Terapia Genica e Cellulare

Laboratori 2022/2023 - Terapia Genica e Cellulare

Di seguito è possibile visionare l’elenco dei Supervisori (e i link ai rispettivi CV) e i progetti presentati per l' a.a. 2022/2022 all'interno del curriculum in Terapia Genica e Celllulare

8 BORSE A PROGETTO:

BORSA A PROGETTO GCT1: AIUTI ALESSANDRO

Unit: Pathogenesis and therapy of primary immunodeficiencies

GCT1: Pre-Clinical development of gene therapy strategies of Lysosomal Storage Disorders

BORSA A PROGETTO GCT2: KAJASTE-RUDNITSKI ANNA

Unit: Retrovirus-host interactions and innate immunity to gene transfer

GCT2:Dissecting Innate Immune Barriers to Efficient Gene Engineering

BORSA A PROGETTO GCT3: OSTUNI RENATO

Unit: Genomics of the Innate Immune System

GCT3: Targeting pathogenic inflammation in pancreatic cancer

BORSA A PROGETTO GCT4: VILLA ANNA

Unit: Pathogenesis and treatment of immune and bone diseases Unit

GCT4: Elucidating the significance of osteopetrotic bone marrow niche in hematopoietic stem and progenitor cells, and its implication for stem cell therapy

BORSA A PROGETTO GCT5: MORTELLARO ALESSANDRA

Unit: Mechanisms of inflammation in health and disease

GCT5: INVESTIGATION OF NOVEL PATHWAYS CAUSING AUTOINFLAMMATORY DISEASES

BORSA A PROGETTO GCT6: NALDINI LUIGI

Unit: Gene Transfer and New Gene Therapy Strategies Unit

Finanziata su fondi ripartiti ai sensi del DM 9 aprile 2022 n. 352 (M4C2 – Inv. 3.3 - Ricerca PNRR)

Project 1: GCT6: Development of novel selection strategies for gene-edited human hematopoietic stem/progenitor cells

BORSA A PROGETTO GCT7: COLTELLA NADIA

Unit:  Targeted cancer gene therapy

Finanziata su fondi ripartiti ai sensi del DM 9 aprile 2022 n. 352 (M4C2 – Inv. 3.3 - Ricerca PNRR)

GCT7: Optimization of a gene therapy platform for targeted delivery of immune-activating cytokines in the tumor microenvironment of solid tumors and identification of predictive markers of therapeutic response

BORSA A PROGETTO GCT8: CANTORE ALESSIO

Unit: Liver gene therapy

Finanziata su fondi ripartiti ai sensi del DM del 9 aprile 2022 n. 352 (M4C2 – Inv. 3.3 - Ricerca PNRR)

Investigating the efficacy and safety of liver-directed lentiviral gene therapy for glycogen storage disease type-Ia

CHIARA BONINI

Unit: Experimental Hematology

Adoptive cell therapy with genetically engineered T-cells for ovarian cancer

COLASANTE GAIA

Unit: Stem Cell and Neurogenesis

Scn1a gene upregulation mediated by artificial transcription factors to treat Dravet Syndrome

DI MICCO RAFFAELLA

Unit: Senescence in stem cell aging, differentiation and cancer

Dissecting the interplay of cell senescence and the immune system in leukemia response to therapy

NALDINI LUIGI

Unit: Gene Transfer and New Gene Therapy Strategies Unit

Identify key regulators of human HSPCs engraftment in an in vivo hematochimeric model using a gain-of-function screen

RUGGIERO ELIANA

Unit: Experimental hematology

Exploiting cutting edge technologies to hunt novel T cell receptors for the immune gene therapy of acute myeloid leukemia

SCALA SERENA

Unit: Pathogenesis and therapy of primary immunodeficiencies

Studying human Hematopoietic Stem/Progenitor Cell trafficking in vivo

SQUADRITO MARIO LEONARDO

Unit: Targeted cancer gene therapy

Role of tumor-associated Kuppfer cells in liver metastasis seeding and growth

VAGO LUCA

Unit: Immunogenetics, Leukemia Genomics and Immunobiology

Dissecting the Immunobiology of Antileukemic Cell Therapies Through CRISPR/Cas9 Targeted Genome Editing